Noble Financial Keeps Their Buy Rating on Corbus Pharmaceuticals

By Carrie Williams

Noble Financial analyst Mark Jordan reiterated a Buy rating on Corbus Pharmaceuticals (NASDAQ: CRBP) on June 15. The company’s shares closed yesterday at $5.75.

According to, Jordan is a 1-star analyst with an average return of -1.3% and a 46.0% success rate. Jordan covers the Healthcare sector, focusing on stocks such as ContraVir Pharmaceuticals Inc, Adamas Pharmaceuticals, and Anavex Life Sciences.

Currently, the analyst consensus on Corbus Pharmaceuticals is Moderate Buy and the average price target is $24, representing a 317.4% upside.

In a report issued on June 13, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $24 price target.

The company has a one year high of $10.78 and a one year low of $2.62. Currently, Corbus Pharmaceuticals has an average volume of 979.4K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Corbus Pharmaceuticals Holdings, Inc. engages in the development and commercialization of novel therapeutics to treat rare or uncommon chronic and serious inflammatory and fibrotic diseases with clear unmet medical needs. Its produc, JBT-101 is a novel synthetic oral endocannabinoid-mimetic drug that is intended to resolve chronic inflammation and halt fibrotic processes without causing immunosuppression. The company was founded in December 2013 and is headquartered in Norwood, MA.